PEG-MGF is a chemically modified version of mechano growth factor (MGF), a short peptide that corresponds to the C-terminal E-domain of one splice variant of the insulin-like growth factor-1 (IGF-1) gene. The “PEG” refers to polyethylene glycol attached to the peptide, a standard technique for protecting small peptides from rapid breakdown and clearance.
MGF is one of the more contested topics in muscle biology. It was proposed in the 1990s as a locally produced signal released after mechanical loading, and the idea attracted wide interest, but later laboratories questioned whether the synthetic peptide does anything on its own. This article lays out the biology behind MGF, what PEGylation is meant to achieve, the model systems researchers have used, and why the evidence remains unsettled.
At a glance
- Class: PEGylated synthetic peptide derived from the IGF-1Ec (MGF) E-domain
- Origin: MGF concept introduced by Geoffrey Goldspink’s group in the 1990s from studies of IGF-1 splicing in stretched and damaged muscle; PEG conjugation is a later stabilization approach
- Structure: Short E-domain peptide with a polyethylene glycol attachment; peptide sequence, PEG size and molecular weight for each batch are given on the Certificate of Analysis
- Main research areas: IGF-1 splice-variant expression, myoblast and satellite-cell biology, the receptor question, peptide stabilization
- Regulatory status: Not FDA approved; mechano growth factors are listed by WADA under S2
Structure and origin
The IGF-1 gene is alternatively spliced. All of its products encode the same 70-residue mature IGF-1, but they differ in the C-terminal extension, called the E-peptide, that is cleaved off during processing. In humans the three main forms are IGF-1Ea, IGF-1Eb and IGF-1Ec. The human Ec variant corresponds to the rodent form usually called IGF-1Eb. The variants arise from different combinations of exons 4, 5 and 6, which give each E-peptide a distinct sequence.
Goldspink and colleagues reported that one of these splice forms rose sharply in skeletal muscle after stretch or damage, and they named its product mechano growth factor. A 2005 review sets out the full model: mechanical signals change IGF-1 splicing, an early burst of MGF is followed by the more common IGF-1Ea form, and the two are proposed to play different roles in muscle adaptation (Goldspink, 2005).
The MGF E-domain peptide is short and, as a free peptide, is degraded quickly. Research suppliers and some laboratories therefore use modified forms. PEGylation attaches a polyethylene glycol chain, which increases the molecule’s size and shields cleavage sites. The approach is well established for therapeutic proteins, but for MGF specifically the PEG size, attachment site and peptide sequence vary between sources, which is why batch documentation matters.
Mechanism: what the research shows
The core hypothesis is that the E-peptide has activity independent of mature IGF-1. In cultured myoblasts, Yang and Goldspink reported that a synthetic MGF E-domain peptide increased proliferation but not differentiation, whereas mature IGF-1 was associated with differentiation. They also reported that the MGF peptide’s effect was not blocked by an antibody that blocks the IGF-1 receptor, which they took as evidence of a separate mechanism (Yang and Goldspink, 2002).
Other groups tested that idea directly. Brisson and Barton studied IGF-1 E-peptides in cell models with and without the IGF-1 receptor and concluded that E-peptide activity depended on the receptor, suggesting that E-peptides modulate IGF-1 signaling rather than act through a pathway of their own (Brisson and Barton, 2012). In 2014, an editorial titled “The fall of mechanogrowth factor?” discussed new findings that synthetic MGF peptide had no apparent effect on myoblasts or primary muscle stem cells, and reviewed why results in the field have been so inconsistent (Rotwein, 2014).
No dedicated MGF receptor has been identified.
Key areas of study
Splice-variant expression after loading or injury
Studies measure IGF-1Ea and IGF-1Ec transcripts in muscle and other tissues after mechanical loading or damage. One study combined muscle biopsies taken after eccentric exercise in volunteers with in vitro experiments on the synthetic E-peptide (Philippou et al., 2009). Expression studies of this kind are less controversial than studies of the synthetic peptide, because they measure the body’s own transcripts.
Myoblast and satellite-cell biology
Proliferation, differentiation and fusion assays in C2C12 cells and primary muscle precursor cells are the main in vitro models. Results have differed between laboratories and peptide preparations (Yang and Goldspink, 2002; Rotwein, 2014).
Tissue repair beyond muscle
A 2010 minireview summarized reports of MGF expression and activity in tissues beyond skeletal muscle, including heart, bone and the nervous system, and discussed open questions about how the peptide is generated and how it acts (Matheny et al., 2010).
Peptide stabilization
The short half-life of the native E-domain peptide is the reason PEGylated and otherwise modified versions exist. Comparative data on how PEGylation changes MGF’s activity are sparse in the peer-reviewed literature.
What the evidence does not show
- The central claim, that the MGF E-peptide acts independently of IGF-1, is disputed. Some laboratories report clear effects; others find none or find the effects depend on the IGF-1 receptor.
- It is not established that a free MGF peptide circulates or acts in vivo in the form that synthetic versions mimic.
- Peer-reviewed studies specifically on PEGylated MGF are very limited, so most statements about PEG-MGF are extrapolated from work on unmodified or differently modified E-domain peptides.
- Synthetic peptide sequences and modifications differ between studies, which makes results hard to compare.
- PEG-MGF has no approved drug equivalent, and there are no controlled studies establishing safety in people.
Regulatory status
PEG-MGF is not approved by the FDA for any use, and it has no approved drug equivalent. Mechano growth factors are covered by the World Anti-Doping Agency’s Prohibited List under S2 (peptide hormones, growth factors, related substances and mimetics). Rogue Compounds sells it as a research reagent only.
Handling and storage in the lab
Keep the lyophilized material sealed and refrigerated at 2–8°C (36–46°F), protected from light.
Sourcing and documentation
PEG-MGF is made in small batches for Rogue Compounds. Every vial carries a batch number and a QR code that opens the independent U.S. testing lab’s own report for that batch, and the same batch COA is on the product page and in the COA Library.
View PEG-MGF on Rogue Compounds
References
- Goldspink G. Mechanical signals, IGF-I gene splicing, and muscle adaptation. Physiology (Bethesda). 2005;20. PMID 16024511
- Yang SY, Goldspink G. Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation. FEBS Lett. 2002;522(1-3):156-160. PMID 12095637
- Philippou A, et al. Expression of IGF-1 isoforms after exercise-induced muscle damage in humans: characterization of the MGF E peptide actions in vitro. In Vivo. 2009;23(4). PMID 19567392
- Matheny RW Jr, Nindl BC, Adamo ML. Minireview: mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration. Endocrinology. 2010;151:865-875. PMID 20130113
- Brisson BK, Barton ER. Insulin-like growth factor-I E-peptide activity is dependent on the IGF-I receptor. PLoS One. 2012;7(9). PMID 23029120
- Rotwein P. Editorial: the fall of mechanogrowth factor? Mol Endocrinol. 2014;28(2):155-156. PMID 24460193
Research use only. Rogue Compounds products are sold strictly for laboratory research. They are not for human or veterinary use, and nothing in this article is medical advice. The studies cited here describe published research, not this product or any use of it.